Live prices from 16 UK suppliers, from £40.00, compared side by side so you never overpay.
Copy the code — you'll paste it at checkout.
with our exclusive code
You're about to visit an external supplier
with our exclusive code
By clicking "Continue", you acknowledge that you understand and accept the above. Read our full disclosure.
Mazdutide
Mazdutide 10mg (Dual GLP-BI-362)
Mazdutide
Mazdutide 10mg
Mazdutide 10mg
Mazdutide 10mg
Mazdutide
Compare 13 prices for Mazdutide. Cheapest: £49.95. Average: £102.20.
| Compare | Visit | |||||||
|---|---|---|---|---|---|---|---|---|
| £109.99 | £11.00/mg | Out of Stock | Free |
Lab Tested
|
— | |||
| £110.99 | £11.10/mg | In Stock | Free |
Lab Tested
|
— | |||
| £54.95 | £5.50/mg | Out of Stock | Free over £75 |
Lab Tested
|
— | |||
| £49.95 | £5.00/mg | In Stock | Free |
Lab Tested
|
— | Unavailable | ||
| £114.75 | £11.48/mg | In Stock | Free |
—
|
— | |||
| £313.60 | £31.36/mg | In Stock | Free over £100 |
Lab Tested
|
— | |||
| £64.95 | £6.50/mg | In Stock | Free |
Lab Tested
|
— | |||
| £54.50 | £5.45/mg | In Stock | Free |
Lab Tested
|
— | Unavailable | ||
| £55.89 | £5.59/mg | In Stock | Free |
—
|
— | |||
| £65.00 | £6.50/mg | In Stock | Free |
—
|
— | |||
| £65.00 | £6.50/mg | Out of Stock | £9.99 |
—
|
— | |||
| £69.00 | £6.90/mg | Low Stock | Free over £200 |
Lab Tested
|
— | |||
| £199.99 | £20.00/mg | In Stock | Free |
Lab Tested
|
— | Unavailable |
More ways to compare Mazdutide
Different views of the same live UK pricing, tuned for how you like to shop.
Compare another peptide
All purchases are made directly from third-party suppliers; your relationship is solely with them. We accept no liability for the quality, purity, or legality of any products listed.
We may earn a commission when you click through to a supplier and make a purchase. This does not affect pricing information displayed.
By using this site you accept responsibility for ensuring purchases comply with applicable laws in your jurisdiction. Read our full disclosure.
Dual GLP-1/Glucagon Receptor Agonist | Weight Loss & Diabetes
First-in-class dual GLP-1 and glucagon receptor agonist combining appetite suppression with thermogenesis stimulation. Phase 3 trials demonstrated superiority over semaglutide for weight loss and glycemic control.
Dual agonist activation: GLP-1 stimulates insulin, suppresses glucagon, slows gastric emptying; Glucagon increases energy expenditure and thermogenesis while GLP-1 counteracts glucose-raising effects.
33-amino acid linear synthetic peptide
GLORY-2 demonstrated 20.1% weight loss with 9mg over 60 weeks; 48.7% achieved ≥20% reduction.
Significant reductions in waist circumference, systolic BP (-7.57 mmHg), triglycerides (-43%).
Exploratory analysis showed 80.2% reduction in liver fat, suggesting MASLD/MASH benefits.
HbA1c reductions of 1.41-2.03% across trials; DREAMS-3 showed -2.03% vs semaglutide -1.84%.
48% achieved HbA1c <7.0% AND ≥10% weight loss versus 21% with semaglutide.
Systolic reduction of -7.57 mmHg, diastolic -2.98 mmHg in clinical trials.
Total cholesterol -16.82%, triglycerides -43.29%, LDL -17.07%.
Subcutaneous injection delivering dual GLP-1/glucagon agonism with once-weekly dosing enabled by fatty acid conjugation.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Weight loss initiation (3mg target) | 1.5mg → 3mg | Once weekly | SubQ |
| Weight loss progression (4.5mg target) | 1.5mg → 3mg → 4.5mg | Once weekly | SubQ |
| Weight loss optimization (6mg target) | 2mg → 4mg → 6mg | Once weekly | SubQ |
| Maximum weight loss (9mg target) | 3mg → 6mg → 9mg | Once weekly | SubQ |
| T2D management (mild-moderate) | 3-4.5mg weekly | Once weekly | SubQ |
Both are GLP-1 agonists; combining increases hypoglycemia and severe GI side effect risk.
Both target GLP-1 receptor; additive effects on GI symptoms and hypoglycemia risk.
Another GLP-1 agonist; dual therapy contraindicated due to additive receptor activation.
May require significant dose reduction due to improved glucose control; monitor for hypoglycemia.
Increased hypoglycemia risk; dose reduction may be necessary.
Complementary mechanisms; clinical trials allowed stable metformin use with enhanced efficacy.
No known interactions; may support gut health and potentially reduce GI side effects.
Delayed gastric emptying may affect absorption; separate administration by 1 hour.
Appetite reduction, possible mild nausea, decreased portion sizes
Early weight loss begins (1-2%), improved satiety after meals
Dose escalation phase, GI symptoms typically improving, 3-5% weight loss
Steady weight loss continues (7-12%), energy expenditure effects evident
Significant weight reduction (12-17%), metabolic markers improving
Peak effects (up to 20% weight loss), sustained improvements in BP, lipids, glucose
610 Chinese adults with obesity/overweight; 48 weeks. First Phase 3 weight management trial showing clinically meaningful weight reductions. NEJM.
462 Chinese adults with obesity; 60 weeks; 9mg dose. 20.1% weight loss vs 2.8% placebo; 48.7% achieved ≥20% reduction; no plateau observed.
349 Chinese adults with T2D and obesity; 32 weeks. Mazdutide superiority: 48% vs 21% achieved HbA1c <7.0% AND ≥10% weight reduction (p<0.0001).
Chinese adults with T2D; 20 weeks. HbA1c reductions 1.41-1.67% vs 0.03% placebo; weight loss up to 7.1%. Diabetes Care.
Be the first to know when prices drop on your favourite peptides
No spam. Unsubscribe anytime. We respect your privacy.